Good news for tinnitus patients: The tinnitus therapy device tinniwell is paid by health insurances in Switzerland and Germany. After approval by an expert physician, the tinniwell is already taken over by Helsana and Swica, depending on the tariff of the patients. In Germany, depending on the tariff of the insured person, the full purchase price will be reimbursed by the private health insurance company Continentale.
For Resaphene Suisse AG, this milestone means that the developed therapy procedure can now become the standard in the treatment of chronically subjective tonal decompensated tinnitus. For the health insurance companies a big cost reduction is possible here. So far, money has been spent continuously for years on therapeutically meaningless procedures without proof of effectiveness.Back